Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaloacetate in Alzheimer's Disease (TOAD)
NCT02593318Phase 1Completed
- Sponsor
- Russell Swerdlow
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxaloacetate in Alzheimer's disease (AD) (2 arms), sponsored by Russell Swerdlow. Primary endpoint: Number of Dose Limiting Toxicity Events at 4 weeks. Started Oct 2015; status: completed.
02
Drugs
oxaloacetate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02593318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593318.